ALK-i resistance may be due to the conversion to small cell lung cancer (SCLC) or squamous cell carcinoma (SCC): Kaiho et al. reported a rare case of a patient with diagnosis of ALK-rearranged adenocarcinoma that transformed to SCC after alectinib and was not responsive to ceritinib. Here, ALK is linked to adenocarcinoma.